Reported results
- Total revenue, net was $2.343 million for the third quarter of 2026, compared to $3.083 million for the third quarter of 2025 (GAAP).
- Loss from operations was $6.023 million for the third quarter of 2026, compared to $7.238 million for the third quarter of 2025 (GAAP).
- Non-GAAP Recurring EBITDA was a net loss of $5.032 million for the third quarter of 2026, compared to a net loss of $9.025 million for the third quarter of 2025 (non-GAAP).
- Non-GAAP EBITDA was a net loss of $5.590 million for the third quarter of 2026, compared to a net loss of $9.025 million for the third quarter of 2025 (non-GAAP).
- The Company reduced its outstanding debt balance by $10.1 million in the third quarter of 2026 (GAAP).
Guidance
- The Company expects to file a New Drug Application (NDA) for crofelemer for MVID in mid-2027.
Price and volatility reaction
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.
